This is the authors' abstract. We don't add key points for this paper.
Preoperative nivolumab ± tadalafil is safe in HNSCC and results in more than 50% of the patients having a pathologic treatment response of at least 20% after 4 weeks of treatment. Pretreatment specimens identified HPV status-dependent signatures that predicted response to immunotherapy while posttreatment specimens showed augmentation of the immune microenvironment with the addition of tadalafil.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Luginbuhl et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: